Arkolith/Insider Trading/BTAI/Form 4

Mehta Vimal

CEO and President, DirectorBioXcel Therapeutics, Inc. (BTAI) · full profile →Form 4 · filed Mar 16, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 15, 2026Option exercise(M)219——21K
Mar 14, 2026Option exercise(M)164——21K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 15, 2026Option exercise(M)219—$02K
Mar 14, 2026Option exercise(M)164—$0488

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-028722) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML